<?xml version="1.0" encoding="utf-8"?>
    
            

    
        



    <rss xmlns:content="http://purl.org/rss/1.0/modules/content/"  version="2.0">
        <channel>
            <title>Recently Published Human Medicines</title>
            <link>https://www.hma.eu//rss/recently-published-human-medicines.html</link>
            <description>New contents from the website www.hma.eu. Category: Recently Published Human Medicines</description>
            <language>en</language>
            <copyright>Heads of Medicines Agencies</copyright>
            <pubDate>Wed, 18 Nov 2026 14:18:14 +0100</pubDate>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[Added in November 2026
18 November
NEW - Report from the meeting held on 10-12 November 2026
17 November
NEW - 13-14 October CMDh MinutesUPDATE - List of active substances for which data has been submitted in accordance with Art. 45
16 November
UPDATE - National recommendations for requests to act as RMSUPDATE - Contact Points
09 November
NEW - 10-12 November CMDh agenda
Added in October 2026
27 October
UPDATE - 'Blue-box' requirements
23 October
UPDATE - Decisions on additional year of market protection/data exclusivity for new therapeutic indication and new active substance status agreed by the CMDh
22 October
UPDATE - MRP/RUP request formUPDATE - 'Blue-box' requirementsUPDATE - List of active substances for which data has been submitted in accordance with Art. 45UPDATE - Request form for RMS in DCPUPDATE - Data requested for Variations and/or Renewal Applications in the MRP/DCPUPDATE - Data requested for New Applications in the MRP/DCPUPDATE - Procedural advice on Validation of MR/Repeat-use/DC ProceduresUPDATE - CMDh Recommendation for classification of unforeseen variations according to Article 5 of Commission Regulation (EC) 1234/2008NEW - Report from the meeting held on 13-14 October 2026
21 October
NEW - 15-17 September CMDh Minutes
12 October
NEW - 13-14 October CMDh agenda
Added in September 2026
29 September
UPDATE - 'Blue-box' requirements
23 September
NEW - PSUR assessment for Iberogast Balance and Iberogast SelectNEW - PSUR assessment for Pyridoxine hydrochloride/ lysozyme hydrochlorideNEW - Recommendations on submission dates in 2027 for Applications of the MRPNEW - Recommendations on submission dates in 2027 for Applications of the DCPNEW - Overview of CMDh referral timetables 2027UPDATE - BPG for the processing of grouped applications in MRP (Chapter 6)NEW - Report from the meeting held on 15-17 September 2026
22 September
UPDATE - Guidance published by Member States on the implementation of the Falsified Medicines DirectiveNEW - 21-22 July CMDh Minutes
16 September
CORRECTION - 24-25 February CMDh minutes
14 September
NEW - 15-17 September CMDh Agenda
Added in August 2026
04 August
UPDATE - Guidance published by Member States on the implementation of the Falsified Medicines Directive
Added in July 2026
29 July
NEW - Report from the meeting held on 21-22 July 2026UPDATE - Template of letter of intent for the submission of a worksharing procedureUPDATE - EMA/CMDh Explanatory notes on Variation Application Form - Human medicinal products onlyUPDATE - Chapter 7 - CMDh BPG on Variation WorksharingUPDATE - Type II variation Preliminary-Final Variation Assessment ReportNEW - 2026 (Jan-Jun) - Statistics for New Applications (MRP/DCP), Variations, Referrals and Paediatric Worksharing procedures
28 July
NEW - 23-25 June CMDh MinutesNEW - Minutes of the 25 June 2026 meeting with Interested Parties
23 July
UPDATE - Contact Points
20 July
NEW - 21-22 July CMDh agenda
03 July
NEW - Summary ARs for doxazosin mesylate/finasterideUPDATE - DCP D70 Overview AR template (incl. instructions) UPDATE - DCP D70 Overview AR template (empty) UPDATE - Instructions for RMS when preparing the PAR based on the FAR UPDATE - PAR template (empty) when prepared based on FARUPDATE - Post-Brexit Q&AUPDATE - Q&A on QP DeclarationUPDATE - Q&A on variationsUPDATE - BPG for the allocation of the MRP variation number for Type I notifications, Type II variations, grouping and worksharing (Chapter 1)UPDATE - BPG for the processing of Type IA minor variations (notifications) in MRP (Chapter 3)UPDATE - BPG for the processing of grouped applications in MRP (Chapter 6)UPDATE - BPG on Variation Worksharing (Chapter 7)UPDATE - Cover letter for variation applications in MRPUPDATE - BPG on the use of eCTD in the MRP/DCPUPDATE - Requirements on submissions for Variations and Renewals within MRP and National Procedures
01 July
NEW - Report from the meeting held on 23-25 June 2026
Added in June 2026
30 June
NEW - 19-20 May CMDh MinutesNEW - Presentations from the 25 June 2026 meeting with Interested Parties
25 June
NEW - Agenda of the CMDh meeting with Interested Parties
22 June
NEW - 23-25 June CMDh agenda
Added in May 2026
27 May
NEW - 21-22 April CMDh MinutesNEW - Art. 46 PAR Rapibloc, Landiolol Hydrochloride Orpha-Devel (landiolol hydrochloride)NEW - Art. 46 PAR Efluelda Tetra (quadrivalent influenza vaccine (split virion, inactivated), 60 micrograms HA/strain)NEW - Art. 46 PAR Vaccin rabique Pasteur, Verorab (rabies virus inactivated (Wistar rabies PM/W138 1503-3M strain))UPDATE - Non Clinical / Clinical AR for Generics - MRP & DCPNEW - Report from the meeting held on 19-20 May 2026
21 May
UPDATE - Contact Points
18 May
NEW - 19-20 May CMDh agenda
07 May
CORRECTION - Questions and Answers on Variations
Added in April 2026
30 April
UPDATE - Contact Points
29 April
UPDATE - List of active substances for which data has been submitted in accordance with Article 45 of the Paediatric Regulation UPDATE - Best Practice Guide for Article 45 and 46 – Paediatric Regulation - EU Worksharing ProcedureUPDATE - CMDh Guidance on the Informal Work-Sharing procedure for follow-up for PSUSA for NAPs (PSUFU procedure) NEW - Report from the meeting held on 21-22 April 2026
28 April
NEW - 24-25 March CMDh Minutes
20 April
NEW - 21-22 April CMDh agenda
07 April
NEW - Ramipril/indapamide PSUR WS SmAR
03 April
UPDATE - Position paper common grounds seen for invalidation/delaying day 0 for variationsUPDATE - Questions and Answers on VariationsUPDATE - Examples for acceptable and not acceptable groupings for MRP/DCP productsUPDATE - Type II variation Preliminary Variation Assessment ReportUPDATE - Chapter 1 - CMDh Best Practice Guide for the allocation of the Mutual Recognition variation number for Type I notifications, Type II variations, grouping and worksharingUPDATE - Chapter 6 - CMDh BPG for the Processing of (Super-)Grouped Applications in the Mutual Recognition ProcedureUPDATE - Questions and answers on the Paediatric RegulationUPDATE - Best Practice Guide for Article 45 and 46 – Paediatric Regulation - EU Worksharing ProcedureUPDATE - D70 Overview AR Template (empty)UPDATE - Overview AR Template (incl. instructions)UPDATE - PAR template (empty) - when prepared based on FARUPDATE - Instructions for RMS when preparing the PAR based on the FARUPDATE - CMDh position paper on the use of Mobile scanning and other technologies to be included in the labelling and/or package leaflet in order to provide information about the medicinal productUPDATE - Annex 2 - Applicant's declaration templateNEW - CMDh Multi-annual Workplan to 2028NEW - CMDh Summary of activities 2025
01 April
NEW - Report from the meeting held on 24-25 March 2026UPDATE - Contact Points
Added in March 2026
31 March
NEW - 24-25 February CMDh Minutes
23 March
NEW - 24-26 March CMDh agenda
04 March
UPDATE - List of active substances for which data has been submitted in accordance with Article 45 of the Paediatric RegulationNEW - Art. 45 PAR Benzocaine / TyrothricinNEW - 2025 Statistics for New Applications (MRP/DCP), Variations, Referrals and Paediatric Worksharing proceduresUPDATE - Q&A on BiologicalsNEW - CMDh Multi-Annual Workplan to 2025 - Summary ReportNEW - Report from the meeting held on 24-25 February 2026NEW - Overview of biological active substances of non-recombinant originNEW - 27-28 January CMDh Minutes
03 March
CORRECTION - 09-11 December CMDh minutesCORRECTION - Report from the meeting held on 9-11 December 2025
Added in February 2026
24 February
NEW - 24-25 February CMDh agenda
13 February
UPDATE - Q&A on Generics
10 February
NEW - Art. 46 PAR Elvanse (lisdexamfetamine dimesylate)NEW - Art. 46 PAR Pneumovax and associated names (pneumococcal polysaccharide vaccine)
04 February
NEW - Report from the meeting held on 27-28 January 2026
03 February
NEW - 09-11 December CMDh minutes
Added in January 2026
27 January
UPDATE - Contact PointsNEW - 27-29 January CMDh agenda
19 January
UPDATE - National recommendations for requests to act as RMS
08 January
CORRECTION - CMDh Recommendation for classification of unforeseen variations according to Article 5 of Commission Regulation (EC) 1234/2008 
07 January
UPDATE - ASMF Worksharing Procedure User Guide
Added in December 2025
18 December
UPDATE - List of active substances for which data has been submitted in accordance with Article 45 of the Paediatric RegulationUPDATE - EMA/CMDh Explanatory notes on Variation Application Form - Human medicinal products onlyCORRECTION - Q&A Submission of variations for human medicinal productsUPDATE - Hormone Replacement Therapy - Core SmPCUPDATE - Hormone Replacement Therapy - Core Package Leaflet
17 December
NEW - PSUFU Levonorgestrel intra-uterine devices (LNG-IUDs)NEW - PSUR WS summary AR nebivolol hydrochloride/amlodipine besilateNEW - Art. 45 PAR Mycobutin (rifabutin)NEW - Art. 45 PAR Prothyrid 100 microgram/10 microgram (levothyroxine sodium/liothyronine hydrochloride)NEW - Art. 45 PAR Cynomel 0,025 mg, Thyrotardin inject (liothyronine sodium) / Thybon 20 Henning. Thybon 100 Henning (liothyronine hydrochloride)UPDATE - National recommendations for requests to act as RMSUPDATE - CMDh Best Practice Guide on Variation Worksharing, Chapter 7NEW - Report from the meeting held on 9-11 December 2025NEW - 11-13 November CMDh minutesNEW - Minutes of the 19 November 2025 meeting with Interested Parties
8 December
NEW - 9-11 December CMDh agenda]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh/recently-published-history.html#c7757</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh/recently-published-history.html#c7757</guid>
                    <pubDate>Tue, 08 Oct 2024 14:35:09 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[CMDH PRESS RELEASES 2026]]></title>
                    <description><![CDATA[Report from the meeting held on 10-12 November 2026Report from the meeting held on 13-14 October 2026Report from the meeting held on 15-17 September 2026Report from the meeting held on 21-22 July 2026Report from the meeting held on 23-25 June 2026Report from the meeting held on 19-20 May 2026Report from the meeting held on 21-22 April 2026Report from the meeting held on 24-25 March 2026Report from the meeting held on 24-25 February 2026Report from the meeting held on 27-28 January 2026]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh/press-releases.html#c7863</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh/press-releases.html#c7863</guid>
                    <pubDate>Tue, 03 Feb 2026 17:20:16 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[National recommendations for requests to act as RMS  (November 2026)]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh/procedural-guidance/application-for-ma/dcp.html#c5513</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh/procedural-guidance/application-for-ma/dcp.html#c5513</guid>
                    <pubDate>Tue, 14 Dec 2021 12:54:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[Meeting 10-12 November: AgendaMeeting 13-14 October: Agenda - MinutesMeeting 15-17 September: Agenda - MinutesMeeting 21-22 July 2026: Agenda - MinutesMeeting 23-25 June 2026: Agenda - MinutesMeeting 19-20 May 2026: Agenda - MinutesMeeting 21-22 April 2026: Agenda - MinutesMeeting 24-25 March 2026: Agenda - MinutesMeeting 24-25 February 2026: Agenda - Minutes - Correction 16/09/2026Meeting 27-29 January 2026: Agenda - Minutes]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh/agendas-and-minutes.html#c7862</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh/agendas-and-minutes.html#c7862</guid>
                    <pubDate>Wed, 21 Jan 2026 13:06:11 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[List of active substances for which data has been submitted in accordance with Article 45 of the Paediatric Regulation]]></title>
                    <description><![CDATA[List of active substances for which data has been submitted in accordance with Article 45 of the Paediatric Regulation (November 2026)]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh/paediatric-regulation/article-45-and-previous-worksharing.html#c2202</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh/paediatric-regulation/article-45-and-previous-worksharing.html#c2202</guid>
                    <pubDate>Thu, 30 Sep 2021 17:00:00 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[Member: Sigridur Kristinsdottir
Icelandic Medicines AgencyVinlandsleid 14IC-113 Reykjavik]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh/about-cmdh/cmdh-composition.html#c5363</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh/about-cmdh/cmdh-composition.html#c5363</guid>
                    <pubDate>Thu, 01 Jan 1970 01:00:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[Contact Points]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh/contact-points.html#c4478</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh/contact-points.html#c4478</guid>
                    <pubDate>Thu, 07 Oct 2021 14:43:00 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[At the request of a Member State the PRAC may issue an advice concerning risk management plans/systems, renewals or safety type II variations that can affect the product information
Recommendation for update of product information is published in CMDh Press Release or CMDh minutes 
The below table provides an overview of PRAC advice to Member States (MSs) and high-level summaries of the corresponding CMDh outcomes. It aims to improve transparency and facilitate the identification of nationally authorised medicinal products for which PRAC advice has been provided during a variation or new marketing authorisation application. This compilation includes cases discussed by the CMDh from July 2026 onwards only.
Compilation of outcomes of PRAC advice to Member States]]></description>
                    <link>https://www.hma.eu//shortcut-page-for-pharmacovigilance-procedures-outcomes/outcome-of-prac-advice.html#c7392</link>
                    <guid>https://www.hma.eu//shortcut-page-for-pharmacovigilance-procedures-outcomes/outcome-of-prac-advice.html#c7392</guid>
                    <pubDate>Fri, 04 Aug 2023 16:05:02 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[Questions and answers
A question-and-answer document is available for marketing authorisation holders on implementing the Article 5(3) CHMP opinion. It covers the following:
Outcome of the Article 5(3) referral and its relation to lessons learned exercise from nitrosamines detected in sartansPrinciples, methodology and scope for nitrosamine management in human authorised productsGuidance for establishing and reporting acceptable intake limits derived from implemented approaches: carcinogenic potency categorisation approach (CPCA), read across (SAR) and in vitro (EAT) / in vivo studies.Changes to marketing authorisations and requirements for new applicationsNew approaches for setting nitrosamines limits based on robust scientific knowledge about carcinogenic potency, including the Appendix 1 on acceptable intakes established for N-nitrosamines, Appendix 2 on the carcinogenic potency categorisation approach (CPCA), and Appendix 3 on the enhanced AMES test (EAT) protocol.
CHMP and CMDh agreed on an updated question-and-answer document in November 2026.
The latest version of this document reflects several changes in the policies and recommendations published to date, such as:

Higher AI limits for nitrosamines impurities, as a result of the full application of the less than lifetime (LTL) approach in ICH M7 for eligible medicines intended for treatments of duration of less than 10 years (see Q&A 24)Extension of the CAPA implementation period from 3 to 7 years, under certain conditions (see Q&A 22)Inclusion of a new risk factor for nitrosamine formation linked to parenteral products packaged in polymer bags (see Q&A 4)Applicability of the approach to establish AI limits for nitrosamines to other N-Nitroso compounds (see Q&A 23)Update on limits for nitrosamines originating from excipients (see Q&A 10)
Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products
Appendix 1: Acceptable intakes established for N-nitrosamines
Appendix 2 : Carcinogenic Potency Categorisation Approach for N-nitrosamines
Appendix 3 : Enhanced Ames Test Conditions for N-nitrosamines
 ]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh/nitrosamine-impurities.html#c7607</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh/nitrosamine-impurities.html#c7607</guid>
                    <pubDate>Thu, 19 Dec 2024 13:42:50 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[List of documents published on CMDh website (October 2026)(to be used to locate documents on the CMDh website)]]></description>
                    <link>https://www.hma.eu//human-medicines/cmdh.html#c2090</link>
                    <guid>https://www.hma.eu//human-medicines/cmdh.html#c2090</guid>
                    <pubDate>Tue, 01 Dec 2015 14:47:00 +0100</pubDate>
                </item>
            
        </channel>
    </rss>




    


        



